11 results on '"Procopio, Antonio Domenico"'
Search Results
2. Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study
- Author
-
Sabbatinelli, Jacopo, Giuliani, Angelica, Bonfigli, Anna Rita, Ramini, Deborah, Matacchione, Giulia, Campolucci, Carla, Ceka, Artan, Tortato, Elena, Rippo, Maria Rita, Procopio, Antonio Domenico, Moretti, Marco, and Olivieri, Fabiola
- Published
- 2022
- Full Text
- View/download PDF
3. CD31+ Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications.
- Author
-
Prattichizzo, Francesco, De Nigris, Valeria, Sabbatinelli, Jacopo, Giuliani, Angelica, Castaño, Carlos, Párrizas, Marcelina, Crespo, Isabel, Grimaldi, Annalisa, Baranzini, Nicolò, Spiga, Rosangela, Mancuso, Elettra, Rippo, Maria Rita, Procopio, Antonio Domenico, Novials, Anna, Bonfigli, Anna Rita, Garavelli, Silvia, La Sala, Lucia, Matarese, Giuseppe, de Candia, Paola, and Olivieri, Fabiola
- Subjects
EXTRACELLULAR vesicles ,TYPE 2 diabetes ,MICRORNA ,RNA metabolism ,RESEARCH ,DIABETIC cardiomyopathy ,CROSS-sectional method ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,EPITHELIAL cells - Abstract
Innovative biomarkers are needed to improve the management of patients with type 2 diabetes mellitus (T2DM). Blood circulating miRNAs have been proposed as a potential tool to detect T2DM complications, but the lack of tissue specificity, among other reasons, has hampered their translation to clinical settings. Extracellular vesicle (EV)-shuttled miRNAs have been proposed as an alternative approach. Here, we adapted an immunomagnetic bead-based method to isolate plasma CD31+ EVs to harvest vesicles deriving from tissues relevant for T2DM complications. Surface marker characterization showed that CD31+ EVs were also positive for a range of markers typical of both platelets and activated endothelial cells. After characterization, we quantified 11 candidate miRNAs associated with vascular performance and shuttled by CD31+ EVs in a large (n = 218) cross-sectional cohort of patients categorized as having T2DM without complications, having T2DM with complications, and control subjects. We found that 10 of the tested miRNAs are affected by T2DM, while the signature composed by miR-146a, -320a, -422a, and -451a efficiently identified T2DM patients with complications. Furthermore, another CD31+ EV-shuttled miRNA signature, i.e., miR-155, -320a, -342-3p, -376, and -422a, detected T2DM patients with a previous major adverse cardiovascular event. Many of these miRNAs significantly correlate with clinical variables held to play a key role in the development of complications. In addition, we show that CD31+ EVs from patients with T2DM are able to promote the expression of selected inflammatory mRNAs, i.e., CCL2, IL-1α, and TNFα, when administered to endothelial cells in vitro. Overall, these data suggest that the miRNA cargo of plasma CD31+ EVs is largely affected by T2DM and related complications, encouraging further research to explore the diagnostic potential and the functional role of these alterations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes.
- Author
-
Prattichizzo, Francesco, Giuliani, Angelica, Sabbatinelli, Jacopo, Matacchione, Giulia, Ramini, Deborah, Bonfigli, Anna Rita, Rippo, Maria Rita, Candia, Paola, Procopio, Antonio Domenico, Olivieri, Fabiola, and Ceriello, Antonio
- Subjects
TYPE 2 diabetes ,ATHEROSCLEROSIS ,GLYCEMIC control ,CARDIOVASCULAR diseases risk factors ,WAIST-hip ratio - Abstract
Residual inflammatory risk (RIR) is defined as persistent circulating levels of high sensitivity C‐reactive protein (hs‐CRP) >2 mg/L despite an optimal (<70 mg/dL) control of LDL‐cholesterol (LDL‐C) and represents an emerging risk factor for the development of cardiovascular events in patients at high risk of atherosclerosis. Sparse data are available regarding the prevalence of RIR in patients with type 2 diabetes (T2D) and the clinical variables associated with hs‐CRP elevation. Here, we report data from a well‐characterized cohort of patients with T2D (n = 511) stratified for statins use, LDL‐C goal attainment and prevalent T2D complications. Statins use and having at‐target LDL‐C partially affect the number of patients with inflammatory risk when compared with the whole T2D population, with an RIR prevalence of 39.2%. Among the spectra of complications, only patients with nephropathy had a higher prevalence of inflammatory risk. Total cholesterol, non‐HDL‐cholesterol, triglycerides, body mass index and waist‐hip ratio were associated with hs‐CRP, with an increased magnitude in at‐target patients. Conversely, glucose‐related variables were strongly associated with hs‐CRP only in at‐target patients, overall suggesting glycaemic control, insulin resistance, non‐LDL‐C lipid variables and especially central obesity as possible contributors to RIR in patients with T2D and LDL‐C <70 mg/dL. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Where Metabolism Meets Senescence: Focus on Endothelial Cells.
- Author
-
Sabbatinelli, Jacopo, Prattichizzo, Francesco, Olivieri, Fabiola, Procopio, Antonio Domenico, Rippo, Maria Rita, and Giuliani, Angelica
- Subjects
ENDOTHELIAL cells ,NITRIC-oxide synthases ,POLY ADP ribose ,CARDIOVASCULAR diseases ,METABOLISM ,PATHOLOGY ,NAD (Coenzyme) - Abstract
Despite the decline in their proliferative potential, senescent cells display a high metabolic activity. Senescent cells have been shown to acquire a more glycolytic state even in presence of high oxygen levels, in a way similar to cancer cells. The diversion of pyruvate, the final product of glycolysis, away from oxidative phosphorylation results in an altered bioenergetic state and may occur as a response to the enhanced oxidative stress caused by the accumulation of dysfunctional mitochondria. This metabolic shift leads to increased AMP/ATP and ADP/ATP ratios, to the subsequent AMPK activation, and ultimately to p53-mediated growth arrest. Mounting evidences suggest that metabolic reprogramming is critical to direct considerable amounts of energy toward specific activities related to the senescent state, including the senescence-associated secretory phenotype (SASP) and the modulation of immune responses within senescent cell tissue microenvironment. Interestingly, despite the relative abundance of oxygen in the vascular compartment, healthy endothelial cells (ECs) produce most of their ATP content from the anaerobic conversion of glucose to lactate. Their high glycolytic rate further increases during senescence. Alterations in EC metabolism have been identified in age-related diseases (ARDs) associated with a dysfunctional vasculature, including atherosclerosis, type 2 diabetes and cardiovascular diseases. In particular, higher production of reactive oxygen species deriving from a variety of enzymatic sources, including uncoupled endothelial nitric oxide synthase and the electron transport chain, causes DNA damage and activates the NAD
+ -consuming enzymes polyADP-ribose polymerase 1 (PARP1). These non-physiological mechanisms drive the impairment of the glycolytic flux and the diversion of glycolytic intermediates into many pathological pathways. Of note, accumulation of senescent ECs has been reported in the context of ARDs. Through their pro-oxidant, pro-inflammatory, vasoconstrictor, and prothrombotic activities, they negatively impact on vascular physiology, promoting both the onset and development of ARDs. Here, we review the current knowledge on the cellular senescence-related metabolic changes and their contribution to the mechanisms underlying the pathogenesis of ARDs, with a particular focus on ECs. Moreover, current and potential interventions aimed at modulating EC metabolism, in order to prevent or delay ARD onset, will be discussed. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing.
- Author
-
Prattichizzo, Francesco, Giuliani, Angelica, Mensà, Emanuela, Sabbatinelli, Jacopo, De Nigris, Valeria, Rippo, Maria Rita, La Sala, Lucia, Procopio, Antonio Domenico, Olivieri, Fabiola, and Ceriello, Antonio
- Subjects
- *
METFORMIN , *MULTIDRUG resistance , *HUMAN microbiota , *TYPE 2 diabetes , *GLUCONEOGENESIS - Abstract
Highlights • Metformin users have a lower incidence of age related diseases. • A summary of appropriate metformin concentrations for in vitro studies is provided. • Metformin has been shown to affect Complex I, AMPK, and glycerophosphate dehydrogenase to inhibit hepatic gluconeogenesis. • Metformin-treated patients differ from diabetic patients treated with other drugs in terms of microbiota composition. • Reshaping of the microbiota could explain the anti-hyperglycaemic and pro-longevity properties of metformin. Abstract Metformin is the first-choice therapy to lower glycaemia and manage type 2 diabetes. Continuously emerging epidemiological data and experimental models are showing additional protective effects of metformin against a number of age-related diseases (ARDs), e.g., cardiovascular diseases and cancer. This evidence has prompted the design of a specific trial, i.e., the Targeting Aging with Metformin (TAME) trial, to test metformin as an anti-ageing molecule. However, a unifying or prevailing mechanism of action of metformin is still debated. Here, we summarize the epidemiological data linking metformin to ARD prevention. Then, we dissect the deeply studied mechanisms of action explaining its antihyperglycemic effect and the putative mechanisms supporting its anti-ageing properties, focusing on studies using clinically pertinent doses. We hypothesize that the molecular observations obtained in different models with metformin could be indirectly mediated by its effect on gut flora. Novel evidence suggests that metformin reshapes the human microbiota, promoting the growth of beneficial bacterial species and counteracting the expansion of detrimental bacterial species. In turn, this action would influence the balance between pro- and anti-inflammatory circulating factors, thereby promoting glycaemic control and healthy ageing. This framework may reconcile diverse observations, providing information for designing further studies to elucidate the complex interplay between metformin and the metabiome harboured in mammalian body compartments, thereby paving the way for innovative, bacterial-based therapeutics to manage type 2 diabetes and foster a longer healthspan. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Inflammageing and metaflammation: The yin and yang of type 2 diabetes.
- Author
-
Prattichizzo, Francesco, De Nigris, Valeria, Spiga, Rosangela, Mancuso, Elettra, La Sala, Lucia, Antonicelli, Roberto, Testa, Roberto, Procopio, Antonio Domenico, Olivieri, Fabiola, and Ceriello, Antonio
- Subjects
- *
INFLAMMATION , *AGING , *TYPE 2 diabetes , *DISEASE progression , *IMMUNE system , *CELLULAR aging - Abstract
Type 2 diabetes mellitus (T2DM) is characterised by chronic low-grade inflammation, recently referred to as ‘metaflammation’, a relevant factor contributing to the development of both diabetes and its complications. Nonetheless, ‘canonical’ anti-inflammatory drugs do not yield satisfactory results in terms of prevention of diabetes progression and of cardiovascular events, suggesting that the causal mechanisms fostering metaflammation deserve further research to identify new druggable targets. Metaflammation resembles ageing-induced low-grade inflammation, previously referred to as inflammageing, in terms of clinical presentation and the molecular profile, pointing to a common aetiology for both conditions. Along with the mechanisms proposed to fuel inflammageing, here we dissect a plethora of pathological cascades triggered by gluco - and lipotoxicity, converging on candidate phenomena possibly explaining the enduring pro-inflammatory program observed in diabetic tissues, i.e. persistent immune-system stimulation, accumulation of senescent cells, epigenetic rearrangements, and alterations in microbiota composition. We discuss the possibility of harnessing these recent discoveries in future therapies for T2DM. Moreover, we review recent evidence regarding the ability of diets and physical exercise to modulate selected inflammatory pathways relevant for the diabetic pathology. Finally, we examine the latest findings showing putative anti-inflammatory mechanisms of anti-hyperglycaemic agents with proven efficacy against T2DM-induced cardiovascular complications, in order to gain insights into quickly translatable therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. CD31 Positive-Extracellular Vesicles from Patients with Type 2 Diabetes Shuttle a miRNA Signature Associated with Cardiovascular Complications
- Author
-
Nicolò Baranzini, Antonio Ceriello, Anna Rita Bonfigli, Elettra Mancuso, Antonio Procopio, Isabel Crespo, Anna Novials, Paola de Candia, Rosangela Spiga, Lucia La Sala, Giuseppe Matarese, Marcelina Párrizas, Annalisa Grimaldi, Fabiola Olivieri, Maria Rita Rippo, Jacopo Sabbatinelli, Francesco Prattichizzo, Silvia Garavelli, Angelica Giuliani, Valeria De Nigris, Carlos Castaño, Prattichizzo, Francesco, De Nigris, Valeria, Sabbatinelli, Jacopo, Giuliani, Angelica, Castaño, Carlo, Párrizas, Marcelina, Crespo, Isabel, Grimaldi, Annalisa, Baranzini, Nicolò, Spiga, Rosangela, Mancuso, Elettra, Rippo, Maria Rita, Procopio, Antonio Domenico, Novials, Anna, Bonfigli, Anna Rita, Garavelli, Silvia, La Sala, Lucia, Matarese, Giuseppe, de Candia, Paola, Olivieri, Fabiola, and Ceriello, Antonio
- Subjects
0301 basic medicine ,CD31 ,endocrine system diseases ,type 2 diabetes mellitus ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,extracellular vesicles ,exosomes ,microRNA ,T2DM complications ,cardiovascular diseases ,MACE ,low-grade inflammation ,Type 2 diabetes ,CCL2 ,Bioinformatics ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,business.industry ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,Extracellular vesicle ,medicine.disease ,030104 developmental biology ,Tumor necrosis factor alpha ,business - Abstract
Innovative biomarkers are needed to improve the management of patients with type 2 diabetes mellitus (T2DM). Blood circulating miRNAs have been proposed as a potential tool to detect T2DM complications, but the lack of tissue specificity, among other reasons, has hampered their translation to clinical settings. Extracellular vesicle (EV)-shuttled miRNAs have been proposed as an alternative approach. Here, we adapted an immunomagnetic bead–based method to isolate plasma CD31+ EVs to harvest vesicles deriving from tissues relevant for T2DM complications. Surface marker characterization showed that CD31+ EVs were also positive for a range of markers typical of both platelets and activated endothelial cells. After characterization, we quantified 11 candidate miRNAs associated with vascular performance and shuttled by CD31+ EVs in a large (n = 218) cross-sectional cohort of patients categorized as having T2DM without complications, having T2DM with complications, and control subjects. We found that 10 of the tested miRNAs are affected by T2DM, while the signature composed by miR-146a, -320a, -422a, and -451a efficiently identified T2DM patients with complications. Furthermore, another CD31+ EV-shuttled miRNA signature, i.e., miR-155, -320a, -342-3p, -376, and -422a, detected T2DM patients with a previous major adverse cardiovascular event. Many of these miRNAs significantly correlate with clinical variables held to play a key role in the development of complications. In addition, we show that CD31+ EVs from patients with T2DM are able to promote the expression of selected inflammatory mRNAs, i.e., CCL2, IL-1α, and TNFα, when administered to endothelial cells in vitro. Overall, these data suggest that the miRNA cargo of plasma CD31+ EVs is largely affected by T2DM and related complications, encouraging further research to explore the diagnostic potential and the functional role of these alterations.
- Published
- 2021
9. Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM
- Author
-
Emanuela Mensà, Fabiola Olivieri, Liana Spazzafumo, Roberto Testa, Anna Rita Bonfigli, Lucia Zampini, Antonio Procopio, Giulia Matacchione, Roberto Antonicelli, Massimiliano Bonafè, Paolo Garagnani, Tiziana Galeazzi, Massimo Boemi, Rina Recchioni, Fiorella Marcheselli, Francesco Prattichizzo, Spazzafumo, Liana, Mensà, Emanuela, Matacchione, Giulia, Galeazzi, Tiziana, Zampini, Lucia, Recchioni, Rina, Marcheselli, Fiorella, Prattichizzo, Francesco, Testa, Roberto, Antonicelli, Roberto, Garagnani, Paolo, Boemi, Massimo, Bonafè, Massimiliano, Bonfigli, Anna Rita, Procopio, Antonio Domenico, and Olivieri, Fabiola
- Subjects
0301 basic medicine ,Gerontology ,medicine.medical_specialty ,business.industry ,Alma mater ,Gerotarget ,aging ,Healthy subjects ,beta galactosidase activity ,Cellular senescence ,Diabetology ,University hospital ,03 medical and health sciences ,Research Paper: Gerotarget (Focus on Aging) ,030104 developmental biology ,Oncology ,Internal medicine ,Age related ,Medicine ,cellular senescence ,In patient ,inflammaging ,type 2 diabetes ,business ,Beta-galactosidase activity - Abstract
// Liana Spazzafumo 1,* , Emanuela Mensa 2,* , Giulia Matacchione 2,* , Tiziana Galeazzi 3 , Lucia Zampini 3 , Rina Recchioni 4 , Fiorella Marcheselli 4 , Francesco Prattichizzo 5 , Roberto Testa 6 , Roberto Antonicelli 7 , Paolo Garagnani 8,9 , Massimo Boemi 10 , Massimiliano Bonafe 8 , Anna Rita Bonfigli 11 , Antonio Domenico Procopio 2,4 and Fabiola Olivieri 2,4 1 Center of Biostatics, INRCA-IRCCS National Institute, Ancona, Italy 2 Department of Clinical and Molecular Sciences, DISCLIMO, Universita Politecnica delle Marche, Ancona, Italy 3 Pediatric Division, Department of Clinical Sciences, Universita Politecnica delle Marche, Ospedali Riuniti, Presidio Salesi, Ancona, Italy 4 Center of Clinical Pathology and Innovative Therapy, INRCA-IRCCS National Institute, Ancona, Italy 5 Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Sesto San Giovanni, Italy 6 Clinical Laboratory and Molecular Diagnostics, INRCA-IRCCS National Institute, Ancona, Italy 7 UTIC-Cardiology INRCA-IRCCS, National Institute, Ancona, Italy 8 Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy 9 Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden 10 Diabetology Unit, INRCA-IRCCS, National Institute, Ancona, Italy 11 Scientific Direction, INRCA-IRCCS, National Institute, Ancona, Italy * The authors contributed equally to this work Correspondence to: Anna Rita Bonfigli, email: // Keywords : cellular senescence; beta galactosidase activity; type 2 diabetes; aging; inflammaging; Gerotarget Received : August 02, 2017 Accepted : October 04, 2017 Published : October 16, 2017 Abstract β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if “age” could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment. A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects. β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normo- and hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition. Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.
- Published
- 2017
10. Pleiotropic effects of polyphenols on glucose and lipid metabolism: Focus on clinical trials.
- Author
-
Matacchione, Giulia, Gurău, Felicia, Baldoni, Simone, Prattichizzo, Francesco, Silvestrini, Andrea, Giuliani, Angelica, Pugnaloni, Armanda, Espinosa, Emma, Amenta, Francesco, Bonafè, Massimiliano, Procopio, Antonio Domenico, Rippo, Maria Rita, Olivieri, Fabiola, and Sabbatinelli, Jacopo
- Subjects
- *
PLANT polyphenols , *GLUCOSE metabolism , *CLINICAL trials , *CATABOLITE repression , *TYPE 2 diabetes , *DISEASE risk factors , *LIPID metabolism - Abstract
• Polyphenols (PPs) are key mediators of the beneficial effects of the Mediterranean Diet. • Dietary PPs can affect glucose and lipid homeostasis through multiple mechanisms. • Clinical trials exploring the effects of PPs on type 2 diabetes and dyslipidemia are affected by multiple sources of bias. • Long-term trials to evaluate the association between PPs and the incidence of type 2 diabetes are needed. Epidemiological evidence from observational studies suggests that dietary polyphenols (PPs) – phytochemicals found in a variety of plant-based foods – can reduce the risk of developing type 2 diabetes mellitus (T2DM). Clinical trials have also indicated that PPs may help manage the two key features of T2DM, hyperglycemia and dyslipidemia. Since the incidence of T2DM is dramatically increasing worldwide, identifying food-based approaches that can reduce the risk of developing it and help manage its main risk factors in early-stage disease has clinical and socioeconomic relevance. After a brief overview of current epidemiological data on the incidence of T2DM in individuals consuming PP-rich diets, we review the evidence from clinical trials investigating PP-enriched foods and/or PP-based nutraceutical compounds, report their main results, and highlight the knowledge gaps that should be bridged to enhance our understanding of the role of PPs in T2DM development and management. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications
- Author
-
Luigina Micolucci, Anna Rita Bonfigli, Roberto Testa, Antonio Domenico Procopio, Francesco Prattichizzo, Emanuela Mensà, Fiorella Marcheselli, Fabiola Olivieri, Liana Spazzafumo, Raffaella Lazzarini, Massimiliano Bonafè, Mirko Gobbi, Massimo Boemi, Rina Recchioni, Roberto Antonicelli, Gabriele Santini, Angelica Giuliani, Olivieri, Fabiola, Spazzafumo, Liana, Bonafè, Massimiliano, Recchioni, Rina, Prattichizzo, Francesco, Marcheselli, Fiorella, Micolucci, Luigina, Mensà, Emanuela, Giuliani, Angelica, Santini, Gabriele, Gobbi, Mirko, Lazzarini, Raffaella, Boemi, Massimo, Testa, Roberto, Antonicelli, Roberto, Procopio, Antonio Domenico, and Bonfigli, Anna Rita
- Subjects
Male ,medicine.medical_specialty ,endocrine system diseases ,Inflammation ,diabetes complication ,Type 2 diabetes ,Gastroenterology ,Proinflammatory cytokine ,Diabetes Complications ,Research Paper: Gerotarget (Focus on Aging) ,Internal medicine ,microRNA ,medicine ,Mir 21 5p ,circulating miRNAs ,Humans ,cardiovascular diseases ,Aged ,Diabetes Complication ,business.industry ,Gerotarget ,Healthy subjects ,nutritional and metabolic diseases ,Middle Aged ,miR-126 ,medicine.disease ,circulating miRNA ,MicroRNAs ,Oncology ,Female ,Endothelium, Vascular ,miR-21 ,type 2 diabetes ,medicine.symptom ,business ,Biomarkers ,Mace - Abstract
Innovative biomarkers are required to manage type 2 diabetic patients (T2DM). We focused our study on miR-126-3p and miR-21-5p levels, as biomarkers of endothelial function and inflammation. MiRNAs levels were measured in plasma from 107 healthy subjects (CTR) and 193 diabetic patients (T2DM), 76 without (T2DM NC) and 117 with (T2DM C) complications. When diabetic complication were analysed as a whole, miR-126-3p and miR-21-5p levels declined significantly from CTR to T2DM NC and T2DM C patients. When miRNAs levels were related to specific complications, significantly higher miR-21-5p levels (0.46 ± 0.44 vs. 0.26 ± 0.33, p < 0.001) and significant lower miR-126-3p levels (0.21 ± 0.21 vs. 0.28 ± 0.22, p = 0.032) were found in T2DM with previous major cardiovascular events (MACE) vs. all the others T2DM patients. To confirm these results we focused on circulating angiogenic cells (CACs) from a subgroup of 10 CTR, 15 T2DM NC and 15 T2DM patients with MACE. CACs from T2DM patients expressed higher miR-21-5p and lower miR-126-3p levels than CACs from CTR. Furthermore, CACs from T2DM + MACE showed the highest levels of miR-21-5p. Circulating miR-21-5p and miR-126-3p emerge as dynamic biomarkers of systemic inflammatory/angiogenic status. Their expression levels in CACs from T2DM with MACE suggest a shift from a proangiogenic to a proinflammatory profile.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.